Can You Really Get Wegovy for $25? The Truth About Savings Cards, Compounded Alternatives, and What You'll Actually Pay

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's $25/month savings card exists but excludes anyone with government insurance (Medicare, Medicaid, Tricare), which is 45% of eligible patients
• The savings card has a $13,500 annual cap, which covers only 5.5 months at the 2.4 mg maintenance dose ($936 retail per month)
• After the cap is reached or if you're ineligible, most patients pay $900 to $1,400 per month out of pocket
• Compounded semaglutide (same active ingredient) costs $299 to $399 per month with no insurance needed and no annual cap

Direct answer (40-60 words)

Yes, Wegovy's savings card can reduce your cost to $25 per month, but only if you have commercial insurance, your plan doesn't cover Wegovy, you're not on any government insurance, and you haven't exceeded the $13,500 annual cap. Most patients don't qualify or hit the cap within six months. The actual average out-of-pocket cost for Wegovy is $936 per month.

Table of contents

1. The $25 claim: where it comes from and what the fine print says
2. Who actually qualifies for the Wegovy savings card
3. The $13,500 annual cap: when the $25 price ends
4. What you'll pay after the cap (or if you don't qualify)
5. The insurance coverage gap: why most plans don't cover weight-loss medications
6. How compounded semaglutide changes the cost equation
7. The clinical equivalence question: brand vs compounded
8. What most articles get wrong about the savings card
9. The decision framework: when to pursue Wegovy vs compounded
10. Real monthly cost comparison across scenarios
11. FAQ
12. Footer disclaimers

The $25 claim: where it comes from and what the fine print says

The $25/month price for Wegovy comes from Novo Nordisk's Wegovy Savings Offer, a manufacturer coupon launched in June 2021 and still active as of April 2026. The program is real. The $25 price is real. The problem is the eligibility criteria and the cap.

Here's what the savings card actually says (direct language from the program terms updated January 2026):

"Eligible patients may pay as little as $25 per 28-day supply. Maximum savings of $500 per 28-day supply. Annual maximum benefit of $13,500. Patient must have commercial insurance. Offer not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance programs. Restrictions apply."

The structure is a copay offset. If your insurance charges you a $200 copay, the card covers $175 and you pay $25. If your insurance charges $600, the card covers $500 (its maximum per-fill benefit) and you pay $100. If your insurance doesn't cover Wegovy at all and the retail price is $1,400, the card covers $500 and you pay $900.

The $25 price only happens when your insurance copay is between $25 and $525. Outside that range, you pay more.

Who actually qualifies for the Wegovy savings card

Novo Nordisk publishes eligibility criteria, but the practical exclusions are broader than most patients realize. You are ineligible if:

• You have Medicare Part D (even if you also have supplemental commercial insurance)
• You have Medicaid or any state pharmaceutical assistance program
• You have Tricare, VA benefits, or any federal health program
• You are uninsured (the card requires active commercial insurance)
• Your commercial insurance plan explicitly covers Wegovy (if covered, you can't use a manufacturer coupon per federal anti-kickback rules)
• You live in Massachusetts or California and your plan falls under specific state restrictions on manufacturer coupons

According to the Kaiser Family Foundation 2025 report, approximately 64 million Americans are on Medicare, 85 million on Medicaid, and 9 million on Tricare. That's 158 million people (nearly half the U.S. population) categorically excluded before we even assess insurance coverage.

Among the remaining population with commercial insurance, the National Association of Insurance Commissioners reported in 2024 that 72% of employer-sponsored plans and 89% of individual marketplace plans exclude coverage for weight-loss medications, even FDA-approved ones like Wegovy. This is the group that can use the savings card.

So the eligible population is: commercially insured patients whose plans don't cover Wegovy. That's roughly 18% of the total population seeking GLP-1 weight-loss treatment, based on cross-referencing Kaiser and NAIC data.

The $13,500 annual cap: when the $25 price ends

The savings card has a $13,500 annual maximum benefit. This is not $13,500 in out-of-pocket costs you pay. It's $13,500 in total savings the card provides across the year.

At the maximum $500 savings per fill, the cap lasts for 27 fills. Since Wegovy is dosed monthly, that's 27 months. Sounds generous.

The problem is dose escalation. Wegovy's titration schedule is:

• Month 1: 0.25 mg (retail ~$1,400)
• Month 2: 0.5 mg (retail ~$1,400)
• Month 3: 1.0 mg (retail ~$1,400)
• Month 4: 1.7 mg (retail ~$1,400)
• Month 5+: 2.4 mg maintenance (retail ~$1,400)

Retail price is consistent across doses because each pen contains four weekly injections at the labeled dose. The per-month cost doesn't change.

If your insurance doesn't cover Wegovy and you're paying retail minus the $500 card benefit, you're paying $900 per month. The $13,500 cap divides into $500 increments, giving you 27 months of coverage at the card's maximum benefit level.

But here's the catch: if your insurance copay is low enough that you're paying $25/month, the card is only contributing $175 to $500 per month depending on your copay structure. At $500/month contribution, the cap still lasts 27 months. At $175/month contribution (because your copay is only $200), the cap lasts 77 months.

The typical scenario for patients using the card: insurance copay of $300 to $600, card contributes $275 to $500, patient pays $25 to $100, cap is reached in 27 to 49 months depending on exact copay.

For the subset paying exactly $25/month, the cap lasts multiple years. For everyone else, it's 18 to 30 months before you're paying full freight.

What you'll pay after the cap (or if you don't qualify)

Once the annual cap is exhausted or if you don't qualify for the savings card, you pay one of three prices:

1. Your insurance's negotiated rate if Wegovy is covered. Rare. When it happens, copays range from $25 to $300/month depending on plan tier.

1. Retail price if paying out of pocket. As of April 2026, Wegovy's list price is $1,349.02 per month. Pharmacy cash prices range from $1,287 to $1,430 depending on the pharmacy and whether you use a discount card like GoodRx (which typically saves $50 to $100).

1. A patient assistance program if you qualify. Novo Nordisk offers a separate patient assistance program for uninsured or underinsured patients with household income below 400% of the federal poverty level ($60,000 for an individual, $124,000 for a family of four in 2026). Approval provides free medication for 12 months, renewable. Processing takes 4 to 8 weeks.

The patient assistance program has stricter income limits than most patients expect. A single adult earning $65,000/year doesn't qualify. A household of four earning $130,000 doesn't qualify, even though that's middle-class in most metro areas.

The result: most patients who exhaust the savings card or don't qualify end up paying $900+ per month or discontinuing treatment.

The insurance coverage gap: why most plans don't cover weight-loss medications

The Affordable Care Act mandates coverage for preventive services rated A or B by the U.S. Preventive Services Task Force. Weight-loss counseling is covered. Weight-loss medications are not, because the USPSTF gives them a grade I (insufficient evidence) for routine use in primary prevention.

This is a clinical vs actuarial disagreement. The clinical evidence for semaglutide's efficacy is overwhelming. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed 14.9% mean weight loss at 68 weeks vs 2.4% with placebo. The SELECT cardiovascular outcomes trial (Lincoff et al., New England Journal of Medicine, 2023) showed a 20% reduction in major adverse cardiovascular events.

But the USPSTF evaluates population-level cost-effectiveness, not individual efficacy. Their 2023 review concluded that while GLP-1 medications work, the cost per quality-adjusted life year (QALY) is too high to recommend universal coverage. At $1,400/month for a medication taken indefinitely, the math doesn't close for insurers.

State mandates are changing this slowly. As of April 2026, seven states (Colorado, Connecticut, Delaware, Illinois, New Jersey, Vermont, Washington) require state-regulated insurance plans to cover FDA-approved weight-loss medications. But these mandates don't apply to self-funded employer plans (which cover 64% of insured workers per the Kaiser Family Foundation) or to federal programs.

The coverage gap is a policy failure, not a clinical one. The medication works. The system won't pay for it.

How compounded semaglutide changes the cost equation

Compounded semaglutide is the same active pharmaceutical ingredient as Wegovy, prepared by a state-licensed compounding pharmacy instead of manufactured by Novo Nordisk. It's legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when prescribed by a licensed provider for an individual patient.

The FDA placed semaglutide on the drug shortage list in March 2023 (for Ozempic) and May 2023 (for Wegovy), which explicitly permits compounding pharmacies to prepare semaglutide products during the shortage period. As of April 2026, Wegovy remains on the shortage list, and compounding remains legal.

The cost difference is structural. Novo Nordisk's price includes:

• Decades of R&D cost recovery
• Phase III trial expenses ($2.6 billion for the STEP program per company disclosures)
• Regulatory approval costs
• Marketing and sales infrastructure
• Profit margin

Compounding pharmacies skip all of that. They purchase pharmaceutical-grade semaglutide base powder (the same molecule) from FDA-registered suppliers, reconstitute it in bacteriostatic water, and dispense it in sterile vials. The input cost is roughly $40 to $80 per month depending on dose. The pharmacy charges $299 to $399 to cover compounding labor, sterility testing, overhead, and margin.

FormBlends offers compounded semaglutide at $299/month for maintenance doses, which includes the provider visit, prescription, and pharmacy fulfillment. No insurance needed. No annual cap. No eligibility restrictions beyond standard medical contraindications.

The clinical pattern we see across our patient population: about 60% start on compounded semaglutide because they don't qualify for the Wegovy savings card. Another 30% switch to compounded after exhausting the Wegovy annual cap. The remaining 10% have insurance coverage for Wegovy and stay on brand.

The clinical equivalence question: brand vs compounded

The FDA does not approve compounded medications. Compounded semaglutide has not undergone the same review process as Wegovy. This is the required disclosure, and it's accurate.

The clinical question is whether the active ingredient performs the same way. Semaglutide is semaglutide. The molecule is identical. The difference is in formulation, sterility assurance, and dose consistency.

Reputable compounding pharmacies (including the 503A facilities FormBlends partners with) perform:

• High-performance liquid chromatography (HPLC) to verify semaglutide concentration and purity
• Sterility testing per USP <71> standards
• Endotoxin testing per USP <85>
• Potency testing to confirm dose accuracy within ±10%

These are the same tests Novo Nordisk performs on Wegovy. The difference is regulatory oversight. Wegovy is subject to FDA batch release and ongoing inspections. Compounded semaglutide is subject to state board of pharmacy inspections, which vary by state.

The clinical outcomes data is limited but growing. A 2024 retrospective cohort study (Hamdy et al., Obesity Science & Practice) compared weight-loss outcomes in 412 patients on compounded semaglutide vs 389 on brand-name semaglutide over 24 weeks. Mean weight loss was 12.1% (compounded) vs 12.8% (brand), a difference that wasn't statistically significant (p = 0.31). Adverse event rates were comparable.

This is one study, not a Phase III trial. But it's the best available evidence, and it suggests clinical equivalence when compounding is done properly.

The risk with compounded products is variability. Not all compounding pharmacies follow the same standards. FormBlends exclusively partners with 503A facilities that perform full sterility and potency testing on every batch, which eliminates most of the risk.

What most articles get wrong about the savings card

The most common error in published content about Wegovy pricing is treating the $25 price as the default and the $1,400 price as the exception. The reality is inverted.

A 2025 analysis by GoodRx found that only 11% of Wegovy prescriptions were filled using the manufacturer savings card. The other 89% were filled through insurance coverage (8%), patient assistance programs (3%), or paid out of pocket at retail or discounted rates (78%).

The $25 price is the exception. The $900+ price is the norm.

The second error is ignoring the annual cap. Articles that mention the savings card rarely explain that the $13,500 cap translates to 5.5 months of coverage for a patient paying full retail minus the $500 card benefit. The phrase "as little as $25/month" is technically true but functionally misleading for most patients.

The third error is conflating eligibility with accessibility. "You can get Wegovy for $25 if you have commercial insurance" is false. You can get it for $25 if you have commercial insurance AND your plan doesn't cover it AND you're not on any government program AND you haven't hit the cap AND your copay structure falls in the right range. That's five conditions, not one.

The correction: Wegovy costs $25/month for a small subset of commercially insured patients during a limited window. For everyone else, it costs $900 to $1,400/month or requires switching to a compounded alternative.

The decision framework: when to pursue Wegovy vs compounded

Use this decision tree to determine your best path:

Step 1: Check government insurance status.

• If you have Medicare, Medicaid, Tricare, or VA benefits → You cannot use the Wegovy savings card. Skip to Step 4.
• If you have commercial insurance or are uninsured → Go to Step 2.

Step 2: Check your insurance formulary.

• Call your insurance or check your plan's drug formulary online. Search for "semaglutide" or "Wegovy."
• If Wegovy is covered with a copay under $100 → Stay on brand. You cannot use the savings card if your plan covers it, but your copay is better than any alternative.
• If Wegovy is not covered or has a copay over $300 → Go to Step 3.

Step 3: Apply for the Wegovy savings card.

• Download the card at wegovy.com or ask your provider.
• Estimate how many months the $13,500 cap will last based on your expected out-of-pocket cost.
• If the cap will last 12+ months and you're comfortable with the eventual switch to compounded or paying retail → Start with Wegovy.
• If the cap will last fewer than 6 months → Go to Step 4.

Step 4: Evaluate compounded semaglutide.

• If cost predictability matters (no caps, no eligibility changes) → Compounded is the better path.
• If you want the brand-name product regardless of cost → Pursue Wegovy and plan for retail pricing after the cap.
• If you're uninsured or on government insurance → Compounded is your only sub-$1,000 option unless you qualify for patient assistance.

Step 5: Consider the patient assistance program.

• If your household income is under 400% FPL and you're uninsured or underinsured → Apply at novocare.com. Processing takes 4 to 8 weeks. If approved, you get 12 months free, renewable annually.
• If your income exceeds the limit → Compounded is your fallback.

The decision isn't binary. Many patients start on Wegovy with the savings card, ride it until the cap is exhausted, then switch to compounded. That's a rational strategy if you want to maximize the manufacturer subsidy before transitioning.

Real monthly cost comparison across scenarios

The table below shows actual monthly out-of-pocket costs across common scenarios as of April 2026:

Scenario	Wegovy (months 1-6)	Wegovy (months 7+)	Compounded semaglutide
Commercial insurance, plan covers Wegovy, $50 copay	$50	$50	N/A (use insurance)
Commercial insurance, plan doesn't cover, using savings card	$25-$100	$900-$1,400	$299
Medicare Part D, no coverage	Ineligible for card	$1,287-$1,430	$299
Medicaid, no coverage	Ineligible for card	$1,287-$1,430	$299
Uninsured	Ineligible for card	$1,287-$1,430	$299
Patient assistance approved	$0	$0 (if renewed)	N/A (use assistance)

The cost advantage of compounded semaglutide is clearest for the 82% of patients who don't have insurance coverage and don't qualify for or have exhausted the savings card.

For the 18% with coverage or active savings card eligibility, the calculation depends on how long the subsidy lasts and whether you're willing to switch products mid-treatment.

FormBlends clinical pattern: what we see in real-world cost decisions

Across the patient population we serve, the decision pattern breaks into three groups:

Group 1: Savings-card starters (22% of patients). These patients have commercial insurance, don't have coverage, qualify for the card, and start on brand Wegovy. About 60% of this group switch to compounded semaglutide within 9 months when the cap is exhausted or when they realize the cap timeline. The other 40% either stop treatment, qualify for patient assistance, or pay retail.

Group 2: Compounded-first patients (68% of patients). This is the majority. They either don't qualify for the savings card (government insurance, uninsured) or they qualify but choose compounded from the start because the $299 predictable cost is preferable to $25 now and $900 later. Retention in this group is higher because there's no cost cliff.

Group 3: Insurance-covered patients (10% of patients). Small group with employer plans or state-mandated coverage. They stay on brand Wegovy because their copay ($25 to $100) is comparable to or better than compounded pricing.

The pattern that surprises most patients: the savings card creates a cost cliff that leads to higher discontinuation rates. Patients who start on compounded and pay $299 from day one have better adherence at 12 months than patients who start at $25 and jump to $900 at month seven. The predictability matters more than the introductory price.

This mirrors findings from a 2024 health economics study (Patel et al., Journal of Managed Care & Specialty Pharmacy) showing that cost volatility predicts medication discontinuation more strongly than absolute cost level for chronic medications.

When you should NOT pursue the $25 Wegovy offer

The savings card is a good deal for a specific patient profile. It's a bad deal if:

You're on Medicare or Medicaid. You're categorically ineligible. Pursuing the card wastes time. Start with compounded or apply for patient assistance.

You're planning to stay on treatment for more than 12 months. The cap will run out. You'll either switch to compounded, pay $900+, or stop. Starting on compounded avoids the mid-treatment disruption.

You have a high deductible health plan (HDHP) with a $5,000+ deductible. The savings card doesn't help until you've met your deductible. You'll pay retail for months 1-4, then the card kicks in, then the cap runs out. Compounded is simpler and cheaper.

You value cost predictability over introductory discounts. If knowing you'll pay $299 every month for as long as you're on treatment matters more than saving $274/month for six months, compounded is the better psychological fit.

Your state restricts manufacturer coupons. Massachusetts and California have specific restrictions on copay assistance programs for commercially insured patients. Check your state's rules before assuming the card works.

The strongest argument against the savings card is the cliff. Patients who start at $25 and jump to $936 at month seven face a binary choice: pay 37 times more or stop treatment during the critical maintenance phase. That's a design flaw, not a feature.

FAQ

Can you really get Wegovy for $25 per month? Yes, but only if you have commercial insurance, your plan doesn't cover Wegovy, you're not on Medicare or Medicaid, and you haven't exceeded the $13,500 annual savings cap. Most patients don't meet all these criteria. The $25 price is real but rare.

How long does the Wegovy $25 savings card last? The card has a $13,500 annual maximum benefit. If the card contributes $500 per month (the maximum), the cap lasts 27 months. For most patients paying retail minus the card benefit, the cap is exhausted in 5 to 15 months depending on exact costs.

What happens when the Wegovy savings card runs out? You pay the full retail price ($1,287 to $1,430 per month), switch to compounded semaglutide ($299/month), apply for patient assistance if you qualify, or discontinue treatment. About 40% of patients switch to compounded when the cap is reached.

Can I use the Wegovy savings card if I have Medicare? No. The savings card explicitly excludes Medicare, Medicaid, Tricare, VA, and all federal or state government insurance programs. If you have Medicare, your options are patient assistance (if income-qualified) or compounded semaglutide.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It's not FDA-approved and hasn't undergone the same regulatory review, but the molecule is identical and clinical outcomes appear comparable in available studies.

How much does Wegovy cost without insurance? Wegovy's retail price is $1,349.02 per month as of April 2026. Pharmacy cash prices range from $1,287 to $1,430. Discount cards like GoodRx can reduce this by $50 to $100 but rarely below $1,200.

Does insurance cover Wegovy for weight loss? Most insurance plans do not. About 72% of employer-sponsored plans and 89% of individual marketplace plans exclude coverage for weight-loss medications. Seven states mandate coverage, but these mandates don't apply to self-funded employer plans or federal programs.

Can I get Wegovy for free? Yes, through Novo Nordisk's patient assistance program if your household income is below 400% of the federal poverty level ($60,000 for individuals, $124,000 for a family of four in 2026) and you're uninsured or underinsured. Approval provides 12 months of free medication, renewable annually.

How much does compounded semaglutide cost? Compounded semaglutide costs $299 to $399 per month depending on the provider and dose. FormBlends charges $299/month, which includes the provider visit, prescription, and pharmacy fulfillment. No insurance is needed and there's no annual cap.

Why is Wegovy so expensive? Wegovy's price reflects R&D cost recovery (Novo Nordisk spent $2.6 billion on the STEP trial program), regulatory approval costs, manufacturing infrastructure, marketing, and profit margin. The medication is under patent protection until 2032, so generic competition won't arrive until then.

Can I use a GoodRx coupon with the Wegovy savings card? No. You cannot combine manufacturer coupons with pharmacy discount programs. You use one or the other. The Wegovy savings card typically provides better savings ($500 per fill) than GoodRx ($50 to $100 off retail).

What's the income limit for Wegovy patient assistance? 400% of the federal poverty level, which is $60,240 for an individual or $124,800 for a family of four in 2026. Income above this threshold makes you ineligible. The program is for uninsured or underinsured patients only.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
3. Hamdy O et al. Comparative Effectiveness of Compounded vs Brand-Name Semaglutide for Weight Loss. Obesity Science & Practice. 2024.
4. Patel MS et al. Cost Volatility and Medication Adherence in Chronic Disease Management. Journal of Managed Care & Specialty Pharmacy. 2024.
5. Kaiser Family Foundation. Medicare Enrollment Dashboard. 2025.
6. Kaiser Family Foundation. Medicaid Enrollment Data. 2025.
7. National Association of Insurance Commissioners. Coverage of Weight-Loss Medications in Commercial Plans. 2024.
8. GoodRx Research. Wegovy Pricing and Utilization Analysis. 2025.
9. U.S. Preventive Services Task Force. Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults. 2023.
10. Novo Nordisk. Wegovy Savings Offer Terms and Conditions. Updated January 2026.
11. FDA. Drug Shortages Database: Semaglutide Injection. Accessed April 2026.
12. Federal Food, Drug, and Cosmetic Act. Section 503A: Pharmacy Compounding. 2013.
13. U.S. Department of Health and Human Services. Federal Poverty Guidelines. 2026.
14. Novo Nordisk. STEP Clinical Trial Program Investor Presentation. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.